IDEXX Laboratories, Inc. Share Price
Equities
IDXX
US45168D1046
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 693.85 USD | +0.41% |
|
-3.01% | +2.56% |
| 15/01 | IDEXX Laboratories, Inc. Launches ImageVue DR50 Plus | CI |
| 15/01 | IDEXX Laboratories, Inc. Advances the Future of Veterinary Cancer Care with Comprehensive Mast Cell Tumor Testing for Dogs | CI |
| Capitalization | 5.54TCr 4.71TCr 4.37TCr 4.08TCr 7.61TCr 5,09000Cr 8.06TCr 50TCr 20TCr 2,40300Cr 21TCr 20TCr 8,74300Cr | P/E ratio 2025 * |
53.7x | P/E ratio 2026 * | 48x |
|---|---|---|---|---|---|
| Enterprise value | 5.62TCr 4.78TCr 4.43TCr 4.14TCr 7.72TCr 5,16200Cr 8.18TCr 51TCr 20TCr 2,43700Cr 21TCr 21TCr 8,86500Cr | EV / Sales 2025 * |
13.1x | EV / Sales 2026 * | 12x |
| Free-Float |
75.42% | Yield 2025 * |
-
| Yield 2026 * | - |
Last Transcript: IDEXX Laboratories, Inc.
| 1 day | +0.41% | ||
| 1 week | -3.01% | ||
| Current month | +2.56% | ||
| 1 month | +0.82% | ||
| 3 months | +8.27% | ||
| 6 months | +26.16% | ||
| Current year | +2.56% |
| 1 week | 681 |  | 709.24 |
| 1 month | 661.89 | | 726.41 |
| Current year | 661.89 | | 726.41 |
| 1 year | 356.14 | | 769.98 |
| 3 years | 356.14 | | 769.98 |
| 5 years | 317.06 | | 769.98 |
| 10 years | 63.48 | | 769.98 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 65 | 28/06/2019 | |
Andrew Emerson
DFI | Director of Finance/CFO | 43 | 01/03/2025 |
Martin Smith
COO | Chief Operating Officer | 58 | 01/01/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
M. Szostak
BRD | Director/Board Member | 75 | 16/07/2012 |
| Director/Board Member | 65 | 23/10/2019 | |
| Director/Board Member | 64 | 15/07/2013 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | +0.75% | 1.59% | 26 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +0.41% | -3.01% | +59.38% | +42.56% | 5.54TCr | |
| Average | +0.41% | -3.01% | +59.38% | +42.56% | 5.54TCr | |
| Weighted average by Cap. | +0.41% | -3.01% | +59.38% | +42.56% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 428.51Cr 364.45Cr 337.81Cr 315.68Cr 588.48Cr 39TCr 623.74Cr 3.86TCr 1.53TCr 19TCr 1.61TCr 1.57TCr 68TCr | 466.17Cr 396.48Cr 367.49Cr 343.42Cr 640.19Cr 43TCr 678.55Cr 4.2TCr 1.67TCr 20TCr 1.75TCr 1.71TCr 74TCr |
| Net income | 104.56Cr 89Cr 82Cr 77Cr 143.6Cr 9.61TCr 152.2Cr 942.07Cr 374.01Cr 4.54TCr 392.08Cr 384.06Cr 16TCr | 115.63Cr 98Cr 91Cr 85Cr 158.79Cr 11TCr 168.3Cr 1.04TCr 413.57Cr 5.02TCr 433.56Cr 424.69Cr 18TCr |
| Net Debt | 78Cr 66Cr 61Cr 57Cr 106.62Cr 7.13TCr 113.01Cr 699.49Cr 277.7Cr 3.37TCr 291.13Cr 285.17Cr 12TCr | 44Cr 37Cr 35Cr 32Cr 60Cr 4.04TCr 64Cr 395.91Cr 157.18Cr 1.91TCr 164.78Cr 161.41Cr 6.93TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23/26/23 | 693.85 $ | +0.41% | 2,79,293 |
| 22/26/22 | 691.05 $ | -0.78% | 4,53,761 |
| 21/26/21 | 696.46 $ | +1.52% | 5,56,558 |
| 20/26/20 | 686.02 $ | -4.10% | 5,60,688 |
| 16/26/16 | 715.37 $ | +0.46% | 5,32,116 |
Delayed Quote Nasdaq, January 24, 2026 at 02:30 am IST
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- IDXX Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition